

Flu Vaccine May Not Be Effective in the Elderly

BY PATRICE WENDLING

CHICAGO — Trivalent inactivated influenza vaccine may not elicit a clinically adequate antibody response in elderly adults, pilot data suggest.

Based on blood assays taken before and 4 weeks after administration of the Fluarix 2007/2008 formula, 88% of 71 community-dwelling older adults (mean age 85 years) failed to mount a fourfold antibody response to any of the three virus strains present in the trivalent influenza vaccine (TIV).

Only two patients had a fourfold antibody response to both influenza A types, H1N1 and H3N2, and none had such a response to all three strains—H1N1, H3N2, and influenza B, Dr. Sean X. Leng said at the annual meeting of the American Geriatrics Society. A fourfold or

The data from the pilot study 'point out the importance of the need for comprehensive evaluation of [the influenza] vaccine in older and frail populations.'

higher vaccine antibody titer increase, also called positive seroconversion, is the criterion for a clinically adequate antibody response.

In contrast, he noted that the vaccine insert reports that 444 (60%) of 745 persons, aged 18-64 years, had a fourfold antibody response to the H1N1 strain, 461 (62%) had such a response to H3N2, and 575 (77%) did so to the influenza B strain.

"Obviously this is pilot data, but [it does] point out the importance of the need for comprehensive evaluation of this vaccine in older and frail populations," commented Dr. Leng, of the division of geriatric medicine and gerontology at Johns Hopkins University in Baltimore.

The audience questioned whether immunity would be a more accurate measure of vaccine protection than antibody response in the elderly since they are more likely than the young to have been vaccinated before and thus would have higher baseline antibody levels.

Of note, researchers at Stanford (Calif.) University recently reported that even the type of vaccine—TIV or live attenuated influenza vaccine—received in prior years affects both serum antibody and B-cell responses to subsequent vaccination (PLoS ONE 2008;8:e2975).

Most patients involved in the current study had high baseline titer levels, which would make it more difficult to achieve positive seroconversion, Dr. Leng acknowledged.

Patients had received flu vaccine for an average of 7 years prior to study entry, although this was based on self-report and subject to memory bias.

Still, 25 (3.4%) of the participants reported having signs and symptoms of

flulike illness during the 2007-2008 flu season, although laboratory confirmation of a diagnosis of influenza was not performed.

There were no reported influenza-related deaths.

Influenza is the fourth-leading cause of death in older Americans, with the elderly bearing more than 90% of influenza-related mortality.

Dr. Leng noted that those aged 75

years and older make up a small percentage of vaccine trial cohorts, despite being the fastest-growing segment of the population. In one vaccine trial, only 11% of patients were at least 75 years old (JAMA 1994;272:1661-5).

The one-size-fits-all approach to influenza vaccine needs to be reexamined, as is being done with cancer screening in elderly and other high-risk groups, he suggested.

Patients in the study ranged in age from 72 to 95 years, 79% were women, and 93% were white. The average number of diagnoses was 3.7; these included hypertension (67%), osteoarthritis (45%), and dyslipidemia (38%).

Dr. Leng and his associates reported no conflicts of interest.

The study was sponsored by the National Institute on Aging and the American Federation for Aging Research. ■

Indications and usage

Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetic treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any

other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

For your patients with type 2 diabetes, start once-daily Levemir®

Levemir® helps patients with diabetes achieve their A1C goal.^{2,3}

- 24-hour action at a once-daily dose^{4,5}
- Provides consistent insulin absorption and action, day after day^{4,6,7}
- Less weight gain^{8*}

To access complimentary e-learning programs, visit novomedlink.com/Levemir

References: 1. Data on file. Novo Nordisk Inc, Princeton, NJ. 2. Meneghini LF, Rosenberg KH, Koenen C, Meriläinen MJ, Lüddeke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418-427. 3. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, for the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetes Care*. 2006;29(6):1269-1274. 4. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes Obes Metab*. 2007;9(3):290-299. 5. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther*. 2006;28(10):1569-1581. 6. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands. Abstract 0189. 7. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*. 2004;53(6):1614-1620. 8. Data on file. NDA21-536. Novo Nordisk Inc, Princeton, NJ.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and Levemir® are registered trademarks of Novo Nordisk A/S.
© 2008 Novo Nordisk Inc. 133236-R2 November 2008

